Total Trades
Politicians Trading
Last Traded
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
Total Trades
Politicians Trading
Last Traded
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
$151.14updated Apr 14, 2026
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Total Trades
6
Politicians Trading
2
Last Traded
Oct 3, 2025
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr.D | Nov 18, 2025 | Oct 3, 2025 | Sell | $1,001 – $15,000 | -3.83% |
| Gilbert Ray Cisneros, Jr.D | Oct 10, 2025 | Sep 22, 2025 | Sell | $1,001 – $15,000 | +4.21% |
| Gilbert Ray Cisneros, Jr.D | Sep 12, 2025 | Aug 8, 2025 | Sell | $1,001 – $15,000 | +37.96% |
| Gilbert Ray Cisneros, Jr.D | Aug 14, 2025 | Jul 7, 2025 | Sell | $1,001 – $15,000 | +55.89% |
| Josh GottheimerD | Jul 16, 2025 | Jun 16, 2025 | Buy | $1,001 – $15,000 | +48.77% |
| Josh GottheimerD | May 14, 2025 | Apr 9, 2025 | Sell | $1,001 – $15,000 | +123.75% |